BioSpace News Archive

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.

InterVenn Biosciences, the life sciences company pioneering glycoproteomic-based diagnostics, announced that Joshua Stahl has been appointed as Chief Executive Officer to guide the company’s next phase of commercial growth.

Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer.

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced four abstracts for four different assets have been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting to be held November 1-5, 2023, in San Diego.

Co-Diagnostics, Inc. announced that Co-Diagnostics will be sponsoring and participating in the Utah Health Care Association/Utah Center for Assisted Living Convention & Expo at the Mountain America Expo Center in Sandy, Utah on September 27-28, 2023.

BeyondSpring Inc. announced the presentation of a poster at the Society for Immunotherapy of Cancer’s 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.

Lunit announced the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC 2023 Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California.

The 2023 Marsh McLennan Agency Charity Classic, benefiting the Pediatric Brain Tumor Foundation, will take place on Wednesday, September 27, with an auction and live broadcast, followed by the annual Cocktails & Cornhole event on October 24.

Milla Pharmaceutical Inc., a subsidiary of the Alter Pharma Group, is now becoming an A.forall company - The Alter Pharma Group, a group of generic and pharmacy sales companies, is rebranding all its brands and businesses into A.forall.

Patient enrollment starting in Q4 2023 for proof-of-concept P2a study of CB1 agonist